Skip Navigation

Nephrology Dialysis Transplantation 2004 19(9):2163-2166; doi:10.1093/ndt/gfh284
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gross, P.
Right arrow Articles by Pistrosch, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, P.
Right arrow Articles by Pistrosch, F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant Vol. 19 No. 9 © ERA-EDTA 2004; all rights reserved


Editorial Comment

Hyperkalaemia: again

Peter Gross and Frank Pistrosch

Nephrology, Department of Medicine, University Medical Center C. G. Carus, Dresden, Germany

Correspondence and offprint requests to: Peter Gross, MD, Nephrologie, Medizinische Klinik III, Universitätsklinikum C. G. Carus, Fetscherstrasse 74, D-01307 Dresden, Germany. Email: peter.gross@mailbox.tu-dresden.de

Keywords: aldosterone antagonists; hyperkalaemia; hyporeninaemic hypoaldosteronism

The first 150 words of the full text of this article appear below.



   Introduction
 
Before 1999—and if one was a nephrologist— it was rare to be called to consult on a case of hyperkalaemia. No doubt cases of hyperkalaemia occurred at that time, too—for instance in patients in the moderate to advanced stages of renal failure—but physicians apparently had sufficient understanding of kidney function to call for dialysis treatment or similar alternative measures where appropriate and take care of severe hyperkalaemia. This has changed recently. Now, it is almost routine to be called by the Emergency Room because of ‘another severe’ hyperkalaemia—and one that is not related to uraemia. Why?



   Hyperkalaemia has changed with the advent of the RALES study
 
In 1999 the ‘randomized aldactone evaluation study investigators’ (RALES [6]) reported the results of a 24 month observation in 1663 patients with advanced congestive heart failure (CHF). In that landmark trial which had been conducted in a prospective controlled fashion, the addition of spironolactone to the patients’ treatment improved morbidity and mortality . . . [Full Text of this Article]



   Hyperkalaemia is now common and it may be fatal
 


   What went wrong after RALES?
 


   What are the risk factors for hyperkalaemia in the setting of ACE inhibitors plus mineralocorticoid antagonist?
 


   Future perspectives
 


   Anything else new in ‘Hyperkalaemia-land’?
 


   Hyporeninaemic hypoaldosteronism (hypo-hypo): an old foe that doesn’t go away
 


   The treatment of hyperkalaemia
 


   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
M. J. Crop, E. J. Hoorn, J. Lindemans, and R. Zietse
Hypokalaemia and subsequent hyperkalaemia in hospitalized patients
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3471 - 3477.
[Abstract] [Full Text] [PDF]